登录

TechnoDerma Brings in ¥10 million in a Series A Round

作者: Mailman 2021-04-22 15:21
特科罗生物
http://www.tkskin.com/
企业数据由 动脉橙 提供支持
皮肤病药物研发商 | PreB轮 | 运营中
中国-四川
2024-01-15
融资金额:数千万人民币
万物资本
查看

(VCBeat) Apr. 07, 2021 -- Jiaxing TechnoDerma Medicines Inc. ("TechnoDerma"), a leader in innovative drugs for skin diseases, announced that it has raised tens of millions in Series A funding round, led by the famous line investment organizations CDH VGC (Venture and Growth Capital), with participation from Oceanpine Healthcare Fund and Linden Asset.


TechnoDerma is a small-molecule drug R&D company focusing on dermatology. The company's current product line includes treatments for hair loss, dermatitis, psoriasis, and lupus erythematosus. TDM-105795, a first-in-class small-molecule drug candidate for the treatment of hair loss due to seborrheic alopecia (also known as androgenic alopecia), has obtained a global intellectual property license. In addition, projects in the R&D pipeline for psoriasis and dermatitis have entered CMC and preclinical studies, with phase I clinical trial application for atopic dermatitis/eczema program expected in early 2022 and phase I application for the psoriasis program expected in late 2022.


TechnoDerma will commercialize its highly selective non-receptor tyrosine-protein kinase (TYK2) inhibitor as a candidate for systemic treatment of lupus erythematosus and other autoimmune-related skin diseases. The company will further expand the R&D pipeline of drugs for skin diseases and accelerate the construction of its R&D team.


TechnoDerma's core drug development team includes Dr.Wang Zengquan, Dr.Li Guanqun, and Dr.Fang Wenkui. The three doctors are all from famous universities, who have studied abroad for many years, and have many years of work experience in well-known pharmaceutical companies. They are all authoritative experts in the field of skin disease research. The three doctors were all rated as "Leading Talents" in Jiaxing City, Zhejiang Province.


>>>>

About CDH VGC


Established in 2002, CDH is one of the leading alternative investment fund managers focused on China today with over US$19 billion of assets under management, as of February 31, 2020. From its roots in private equity, CDH has expanded to become a diversified alternative asset management platform covering: Private Equity, Real Assets, Venture and Growth Capital, Mezzanine & Credit, Public Equities and Wealth Management. CDH VGC focuses on investments in healthcare, TMT and other emerging industries with Chinese characteristics.


>>>>
About Oceanpine Healthcare Fund


Oceanpine Healthcare Fund is a healthcare venture fund that aims to connect innovation in the US to the Chinese consumer base, and primarily invests in Chinese and US firms with core technologies and proprietary R&D capabilities. They bridge a supply and demand gap exacerbated by limited R&D in China. 

相关赛道 化学制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】友芝友生物完成2亿元Pre-C轮融资,加速双特异抗体和新冠疫苗产品临床研发

【首发】玻思韬宣布完成B1轮数亿元融资,加速505(b)(2)创新药物、长效缓释制剂开发

圆因生物完成超亿元Pre-A轮融资,利用环状RNA技术开发疫苗及新型治疗

Yuanqi Biopharma Closes Angel Round of Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

EDDA Technology Secures $150 Million in New Financing Round

2021-04-22
下一篇

Arrail Group Secures $200 Million in Series E Funding

2021-04-22